Today - 2 March 2023

from your office or home

Next Live edition

29 January - 1 February 2024

Dubai World Trade Centre

Surgery without incisions




Wednesday 1st February | 16:30

Transformation Zone | P.L10




  • Introduce the audience to the science of histotripsy, a novel non-ionizing, non-thermal, and non-invasive sonic beam therapy that can mechanically lyse tissue
  • Discuss clinical experience in liver
  • Share future applications of the therapy in other organs

Company bio

HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform deliverers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.



Dr. Juan Jove Vidal
Medical Director and Surgical Oncologist

Degree in Medicine and Surgery from the University of Barcelona, MIR specialist in General and Digestive Surgery, and in Oncological Surgery from George Washington University, Washington DC. PhD in Psychology and Behavioral Sciences, Newport University-Udine. Diploma in Business Administration and Management from IDEC-Pompeu Fabra. FUS-HIFU graduate from Chongqing University, China. Member of the board of the International Society of Therapeutic Ultrasound (ISTU) and the European Focused Ultrasound Foundation (EUFUS). President of the ISTU International Congress – EUFUS International Symposium in Barcelona in 2019. Principal investigator of the first clinical trial of Histotripsia in human liver tumors. Author of numerous conferences and publications, he has awarded prizes and grants for research in oncology, diagnostic imaging and results in health and health services.

For the past 12 years, Dr. Juan Jove Vidal learned the basics of focused ultrasound ablation and led the country’s first FUS-HIFU cancer unit. Since then, he has treated more than 200 patients with tumors of the liver, pancreas and soft tissue. As a scientific surgeon, he has focused his clinical research on the specific impact of ablation on advanced pancreatic and liver tumors, both locally and systemically through the action of immunity. As a doctor, he seeks the good of his patients with care focused on the transcendent dimension of the person.